Press Releases

Press Releases

    Date Title View
    10/22/22
    Summary ToggleNew Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
    PDF Version
    10/13/22
    Summary ToggleHorizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
    PDF Version
    10/12/22
    Summary ToggleHorizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
    PDF Version
    10/06/22
    Summary ToggleHorizon Therapeutics plc Named to Newsweek’s 2022 Top 100 Most Loved Workplaces
    PDF Version
    10/06/22
    Summary ToggleHorizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022
    PDF Version
    10/02/22
    Summary ToggleNew Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
    PDF Version
    09/29/22
    Summary ToggleHorizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
    PDF Version
    09/22/22
    Summary ToggleHorizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner
    PDF Version
    09/21/22
    Summary ToggleHorizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
    PDF Version
    09/19/22
    Summary ToggleHorizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
    PDF Version
    Displaying 11 - 20 of 701 results